SPECIFIC TERMS IN THIS AGREEMENT HAVE BEEN REDACTED BECAUSE SUCH TERMS ARE BOTH NOT MATERIAL AND ARE OF A TYPE THAT ABEONA THERAPEUTICS INC. TREATS AS CONFIDENTIAL. THESE REDACTED TERMS HAVE BEEN MARKED IN THIS EXHIBIT AT THE APPROPRIATE PLACE WITH...License Agreement • August 11th, 2022 • Abeona Therapeutics Inc. • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT (this “Agreement”) is entered into as of May 16, 2022 (the “Effective Date”) by and between Abeona Therapeutics Inc., a Delaware corporation having its principal place of business at 1330 Avenue of the Americas, 33rd Fl, New York, New York 10019, United States (“Abeona”), and Ultragenyx Pharmaceutical Inc., a Delaware corporation having offices at 60 Leveroni Court, Novato, California 94949, United States (“Ultragenyx”).
